Kringle Pharma, Inc. (TYO:4884)

Japan flag Japan · Delayed Price · Currency is JPY
486.00
-3.00 (-0.61%)
Apr 17, 2026, 3:30 PM JST
Market Cap3.57B -41.4%
Revenue (ttm)72.62M -8.7%
Net Income-905.42M
EPS-130.67
Shares Out7.35M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume551,900
Average Volume1,764,330
Open490.00
Previous Close489.00
Day's Range469.00 - 503.00
52-Week Range365.00 - 1,125.00
Beta0.28
RSI60.91
Earnings DateMay 11, 2026

About Kringle Pharma

Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 17
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4884
Full Company Profile

Financial Performance

In fiscal year 2025, Kringle Pharma's revenue was 72.00 million, a decrease of -10.00% compared to the previous year's 80.00 million. Losses were -916.00 million, 21.2% more than in 2024.

Financial Statements